The European Myeloma Network

An overview of the network
History and goals

Important dates
➢ 2005 creation of the network with a small group
➢ 2017 new Bylaw of the EMN
➢ 2019 inclusion of other relevant collaborative groups under the EMN

Our goals
➢ Perform large, international trials in myeloma and related conditions
➢ Uniform standards for correlative studies
➢ Quality control
➢ Consensus, guidelines and recommendations in Europe
➢ Platform for analyses and meta-analyses
➢ Spread knowledge through workshops and meetings
History and goals

Structure
➢ Pan-European organization, non-profit foundation, academic status
➢ Dutch law and bylaws
➢ International Board

Collaboration
➢ National cooperative groups, like Italy, Netherlands, Spain, Nordic, SAKK, Germany etc
➢ Individual centers assigned by national groups (IFM)
➢ Pharmaceutical industry, Diagnostics, Educational partners
➢ Agencies: FDA, EMA
➢ Other stakeholders: EHA, ESMO, IMS
➢ EU projects (Harmony, Predict)
EMN structure 2023
National groups & branches

- Netherlands
- Germany
- France
- Turkey
- Australia
- Italy
- Spain
- Nordic
- UK
- Greek Myeloma Study Group
- Czech Myeloma Study Group
- Pharma Partners
- Regulatory and National Boards
Organization

Board of Directors:
Prof. Sonneveld (President)
Prof. Boccadoro (Vice president)
Prof. Dimopoulos (Member)
Prof. Einsele (Member)
Prof. Ludwig (Member)
Prof. San Miguel (Member)
Prof. Cook (Member)
Prof. Hajek (Member)
Prof. Moreau (Member)
Prof. Schjesvold (Member)

Young EMN Board (operative)
Dr. Broijl  Dr. Radocha
Dr. Gay    Dr. Krauth
Dr. Popat  Dr. Touzeau
Dr. Gavriatopoulou Dr. Ocio
Dr. Rasche Dr. Slordhal

Participants:
Open registration to EMN to be included in the projects and trials of the network.
Registration online is required www.myeloma-europe.org
Organization

*Executive Board (EB)*

Prof. Sonneveld (President)
Prof. Boccadoro (Vice)
Prof. Einsele (Member)
Prof. San Miguel (Member)
Prof. Dimopoulos (Member)
Prof. Ludwig (Member)
Prof. Cook (Member)
Prof. Hajek (Member)
Prof. Moreau (Member)
Prof. Vangsted (Member)

President – Vice President – 2 board members (4 years)

- The EB reports to the Board of Directors and prepares actions and proposals, to be approved by the Board.
- The EB is responsible for annual report and meetings. EB members are appointed by the Board.
- This EB will act as main point of contact/interlocutor of the EMN and it will be directly involved in negotiations with third parties.
TURIN

Italian Administration
Andrea Novali (CFO)
Carla Garbero (HR)
Jelena Dmitrijeva

Clinical Operation
Chiara Pautasso
Giulia Gazzera
Silvia Villa
Antonella Balsamo
Paola Demartini

Medical Writing
Chiara Pautasso
Giulia Gazzera
Silvia Villa
Antonella Balsamo
Paola Demartini

Scientific Secretariat
Dr Merante
Dr Fiore

Pharmacovigilance
Rossella Troia
Paola Colucci
Claudio Vernuccio
Silvia Paglia

Trial StartUp
Jessica Mastrovito
Marta Santoro
Elena Tiganò
Federica Mazzotta
Stefania Arminio

Data Management
Stefano Spada
Antonella Fiorillo
Claudia Priola
Giulia Fumero

IMP Management
Stefano Spada
Debora Calderazzo
Miriana Arminio
Maria José Fornaro

Quality & Compliance
Carla Polimeni
Stefano Spada (training)

COMING SOON

ROTTERDAM

Finance & Legal
Felicia Barbieri
Sylvia Tromp

Trial Lead
Sarah Lonergan

Trial Management
Emelie Asselbergs
Rosita Ghiraw
Ruth Lopez

Validation Lead
Stefano Spada
Andrea Crespo
Angela Jiang
3 freelance staff

Monitoring
Stefano Spada
Andrea Crespo
Angela Jiang
3 freelance staff

IT Consultants
4 freelance staff

System Administrator
Diego Mele

Legal Advisor
Ilaria Petito

PR & Publishing
Giorgio Schirripa
Ugo Panzani
Headquarters and data center

EMN Headquarters – Rotterdam

Data Center EMN Italy - Turin
 Trials

The EMN conducts trials in **myeloma and other rare hematologic conditions:** smoldering myeloma, amyloidosis, plasma cell leukemia

<table>
<thead>
<tr>
<th>EMN study code</th>
<th>Main study drug/s</th>
<th>Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMN01</td>
<td>Lenalidomide</td>
<td>Newly diagnosed transplant-ineligible myeloma</td>
</tr>
<tr>
<td>EMN02</td>
<td>Bortezomib, Lenalidomide</td>
<td>Newly diagnosed transplant-eligible myeloma</td>
</tr>
<tr>
<td>EMN04</td>
<td>Reduced-intensity allogeneic</td>
<td>Relapsed myeloma</td>
</tr>
<tr>
<td>EMN07</td>
<td>Carfilzomib, Pomalidomide</td>
<td>Relapsed/Refractory myeloma</td>
</tr>
<tr>
<td>EMN09</td>
<td>Carfilzomib, Bendamustine</td>
<td>Relapsed/Refractory myeloma</td>
</tr>
<tr>
<td>EMN10</td>
<td>Ixazomib, Bendamustine</td>
<td>Newly diagnosed transplant-ineligible myeloma</td>
</tr>
<tr>
<td>EMN11</td>
<td>Carfilzomib, Pomalidomide</td>
<td>Relapsed/Refractory myeloma</td>
</tr>
<tr>
<td>EMN12</td>
<td>Carfilzomib, Lenalidomide</td>
<td>Newly diagnosed primary plasma cell leukemia</td>
</tr>
<tr>
<td>EMN13</td>
<td>Ixazomib</td>
<td>Relapsed/Refractory myeloma</td>
</tr>
<tr>
<td>EMN14</td>
<td>Pomalidomide, Daratumumab</td>
<td>Relapsed/Refractory myeloma</td>
</tr>
<tr>
<td>EMN15</td>
<td>Carfilzomib, Lenalidomide</td>
<td>Smouldering myeloma</td>
</tr>
<tr>
<td>EMN17</td>
<td>Daratumumab, Bortezomib, Lenalidomide</td>
<td>Newly diagnosed transplant-eligible myeloma</td>
</tr>
<tr>
<td>EMN18</td>
<td>Daratumumab, Bortezomib</td>
<td>Newly diagnosed transplant-eligible myeloma</td>
</tr>
<tr>
<td>EMN19</td>
<td>Daratumumab, Bortezomib</td>
<td>Extramedullary disease</td>
</tr>
<tr>
<td>EMN20</td>
<td>Carfilzomib, Lenalidomide</td>
<td>Newly diagnosed transplant-ineligible myeloma</td>
</tr>
<tr>
<td>EMN22</td>
<td>Daratumumab</td>
<td>Newly diagnosed patients with stage 3B light chain AL amyloidosis</td>
</tr>
<tr>
<td>EMN23</td>
<td>Retrospective, observational</td>
<td>Patients with systemic AL amyloidosis in Europe</td>
</tr>
<tr>
<td>EMN24</td>
<td>Isatuximab, Carfilzomib, Lenalidomide</td>
<td>Newly Diagnosed transplant-eligible myeloma</td>
</tr>
<tr>
<td>EMN26</td>
<td>Iberdomide</td>
<td>Phase 2, maintenance therapy</td>
</tr>
<tr>
<td>EMN27</td>
<td>Belantamab Mafodotin</td>
<td>Relapsed/refractory AL amyloidosis</td>
</tr>
<tr>
<td>EMN28</td>
<td>Cilta-cel CAR-T</td>
<td>Newly diagnosed transplant-eligible myeloma</td>
</tr>
<tr>
<td>EMN29</td>
<td>Selinexor</td>
<td>Relapsed/Refractory myeloma</td>
</tr>
<tr>
<td>EMN30</td>
<td>Teclistamab, lenalidomide</td>
<td>Phase 3, newly diagnosed, maintenance post transplant</td>
</tr>
<tr>
<td>EMN33</td>
<td>MRD procedures (DaraVRd)</td>
<td>Newly diagnosed transplant-eligible myeloma</td>
</tr>
<tr>
<td>EMN34</td>
<td>Elranatamab</td>
<td>Smouldering myeloma</td>
</tr>
<tr>
<td>Covid-19</td>
<td>Data collection</td>
<td>Covid-19 MM patients</td>
</tr>
</tbody>
</table>

**Protocol Review Committee** (scientific & technical) assesses proposals

*Many other studies under definition will be available soon*
Meetings

Discussion of clinical studies and international events to share knowledge

EMN Trialist Forum

➢ Annual meeting of the EMN core investigators
➢ 2-day event in autumn in Baveno – Italy
➢ Discussion of practical issues, amendments and new proposals under the EMN umbrella

EMN annual meeting

➢ Annual workshop for all investigators working in the myeloma field
➢ 3-day 4th EMN Workshop April 2023 in Amsterdam
➢ Educational sessions, Meet the Experts, Symposia & ~500 attendees (no virtual, after Covid19 pandemic)
Collaborative projects

EMN: an umbrella organization for collaborative groups and projects

**HARMONY**

*A public-private European Network of Excellence - January 2017*

**Goal:** to harness and mine Big Data to speed up the development of improved treatments.

**How:** Clinical and translational data are merged together in a big database - 53 partners and 32 associated members from 22 countries, including 8 pharma-companies from EFPIA.

**HORIZON 2020 European Commission framework - MMPredict project**

**Goal:** to clinically validate a personalized medicine tool that predicts the most effective treatment option in myeloma patients.

**How:** SkylineDX is developing a microarray-test that can be used for genetic subtyping of myeloma patients  →  determine the most suitable treatment for patients by predicting their response based on gene expression profiling.
Publications

EHA – European Hematology Association

- E. Kastritis. EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK. Abstract P914.
- E. Kastritis. EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK. Abstract P915.

Original article / full paper on clinical trial or other projects


ASH – American Society of Hematology


Review (more underway – to be published in 2023)

Contacts

The **EMN** staff is pleased to receive any comment, suggestion or proposal.

E-mail addresses:

- [info@emn.life](mailto:info@emn.life)
- [datacenter@emn.life](mailto:datacenter@emn.life)

Website: [www.myeloma-europe.org](http://www.myeloma-europe.org)

*Big objectives can be achieved only through big collaborations*